We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.
- Authors
Vázquez, Luis A.; Tofé-Povedano, Santiago; Bellido-Guerrero, Diego; Botella-Serrano, Marta; Soto-González, Alfonso; Mezquita-Raya, Pedro; Delgado, Elías; Fajardo-Montañana, Carmen; Morales-Portillo, Cristóbal; Causanilles, Ana; Rubio-de Santos, Miriam; Romera, Irene; Jódar-Gimeno, Esteban
- Abstract
Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Due to the potential novelty represented by incorporating tirzepatide to clinical practice, we aim to review practical aspects of tirzepatide use in T2DM and the supporting scientific evidence. A group of ten endocrinologists involved as investigators in the phase 3 SURPASS clinical trial program followed a nominal group technique, a qualitative research methodology designed as a semi-structured group discussion to reach a consensus on the selection of a set of practical aspects. The scientific evidence for tirzepatide has been reviewed with respect to a number of patients' clinical profiles and care goals. Information of interest related to adverse events, special warnings and precautions, and other considerations for tirzepatide use has been included. Finally, information provided to the patients has been summarized. The practical aspects reported herein may be helpful in guiding physicians in the use of tirzepatide and contribute to optimizing the management of T2DM.
- Subjects
TYPE 2 diabetes; ENDOCRINOLOGISTS; GLUCAGON-like peptide-1 receptor; ADULTS
- Publication
Diabetes Therapy, 2024, Vol 15, Issue 7, p1501
- ISSN
1869-6953
- Publication type
Article
- DOI
10.1007/s13300-024-01587-6